Posted inGenetics
Roundup: Removing Impurities from Biomanufacturing
Effective impurity control is critical to biomanufacturing, supporting process, cell line, and formulation stability while preserving biotherapeutic potency and shelf…
Posted inBiotechnology
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
Regeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event…
Posted inGenetics
Your AI Is Only as Good as Your Inputs
Augustė UžuotaitėR&D Supervisor, Genetic SciencesThermo Fisher Scientific Lab leaders are under pressure to adopt AI and automation, and most of…
Posted inBiotechnology
Merck KGaA lays off 20 staffers in latest blow to US research team
The Massachusetts research site for Merck KGaA’s North American division, EMD Serono, has decided to hand pink slips to 20…
Posted inBiotechnology
Schisandrin Lignans Stabilize GPX4 to Suppress Ferroptosis in Drug-Induced Liver Injury
Drug-induced liver injury, one of the most unpredictable complications of modern pharmacotherapy, may be driven by a molecular failure that…
Posted inBiotechnology
GLP-1 Drugs Raise Treatment-Related Stigma Concerns, Researchers Call for Conceptual Clarity
A new commentary in the International Journal of Obesity is drawing attention to a rapidly emerging problem in modern obesity…
Posted inBiotechnology
Bar-Ilan Study Finds Attention Can Regulate Acute Inflammation in Humans
A new study suggests that attention is not merely a way for the brain to interpret sensations from the body.…
Posted inBiotechnology
Scientists find fast-spreading genetic variants causing parasites to resist malaria drugs
Researchers have identified a previously unrecognized set of genetic changes in Plasmodium falciparum, the parasite responsible for the most severe…
Posted inBiotechnology
VRK2 Drives Gemcitabine Resistance in Pancreatic Cancer Through TPI1-Mediated Aerobic Glycolysis
Pancreatic cancer has acquired another layer of biological complexity, according to a new study identifying a molecular pathway that may…
Posted inBiotechnology
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth…